NTMT1: A Potential Drug Target for Various Diseases (G28989)

Target Name: NTMT1

NCBI ID: G28989

NTMT1

NTMT1: A Potential Drug Target for Various Diseases

NTMT1, or N-terminal Xaa-Pro-Lys N-methyltransferase 1 (isoform a), is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NTMT1 is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression in various cellular contexts.

The NTMT1 gene is located on chromosome 6 and encodes a protein that is expressed in various tissues and organs, including brain, muscle, heart, and liver. NTMT1 has been shown to localize to the nuclear envelope and to interact with various protein partners, including histone modifications, non-coding RNAs, and proteins involved in the stress response.

Several studies have demonstrated that NTMT1 is involved in the regulation of cellular processes that are crucial for human health and disease, including cell growth, apoptosis, and inflammation. For example, NTMT1 has been shown to play a role in the regulation of cell cycle progression and to control the timing of cell division. In addition, NTMT1 has been shown to regulate the expression of genes involved in stress response, inflammation, and cellular signaling pathways.

In addition to its role in cellular processes, NTMT1 has also been shown to be involved in the regulation of gene expression in diseases and conditions that are relevant to human health. For example, NTMT1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, NTMT1 has also been shown to be involved in the regulation of cancer cell growth and to play a role in the development of cancer.

Given its involvement in a wide range of cellular processes and its potential involvement in disease, NTMT1 has become an attractive target for research and development of new therapeutic approaches. Several studies have shown that NTMT1 can be modulated using various therapeutic approaches, including small molecules, antibodies, and gene editing techniques. For example, several studies have shown that NTMT1 can be inhibited using small molecules, such as inhibitors of histone modifications or non-coding RNAs, to reduce the activity of NTMT1 and its downstream targets. In addition, NTMT1 has also been shown to be a good candidate for targeted therapies, such as RNA-based therapies or immunomodulatory therapies, by modulating its expression levels or using antibodies to selectively target its function.

In conclusion, NTMT1 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in the regulation of cellular processes and its potential involvement in disease make it an attractive target for research and development of new therapeutic approaches. Further studies are needed to fully understand the function of NTMT1 and its potential as a therapeutic target.

Protein Name: N-terminal Xaa-Pro-Lys N-methyltransferase 1

Functions: Distributive alpha-N-methyltransferase that methylates the N-terminus of target proteins containing the N-terminal motif [Ala/Gly/Pro/Ser]-Pro-Lys when the initiator Met is cleaved. Specifically catalyzes mono-, di- or tri-methylation of the exposed alpha-amino group of the Ala, Gly or Ser residue in the [Ala/Gly/Ser]-Pro-Lys motif and mono- or di-methylation of Pro in the Pro-Pro-Lys motif. Some of the substrates may be primed by NTMT2-mediated monomethylation (PubMed:24090352). Catalyzes the trimethylation of the N-terminal Gly in CENPA (after removal of Met-1). Responsible for the N-terminal methylation of KLHL31, MYL2, MYL3, RB1, RCC1, RPL23A and SET. Required during mitosis for normal bipolar spindle formation and chromosome segregation via its action on RCC1

The "NTMT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NTMT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets